These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32945525)

  • 1. COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.
    Pike A; Muus P; Munir T; Mitchell L; Arnold L; Riley K; Houghton N; Forrest B; Gachev J; Hillmen P; Griffin M
    Br J Haematol; 2020 Oct; 191(1):e1-e4. PubMed ID: 32945525
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report.
    Schüller H; Klein F; Lübbert M; Prager EP
    Ann Hematol; 2021 Mar; 100(3):841-842. PubMed ID: 33170342
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
    Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
    [No Abstract]   [Full Text] [Related]  

  • 4. Neisseria elongata infection associated with complement inhibition during treatment of paroxysmal nocturnal haemoglobinuria.
    Benz R; Krause M; Majer S; Taverna C; Herzog K
    Br J Haematol; 2018 Aug; 182(3):318. PubMed ID: 29676447
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria.
    Pravdic Z; Mitrovic M; Bogdanovic A; Virijevic M; Sabljic N; Pantic N; Vukovic NS
    Hamostaseologie; 2021 Oct; 41(5):397-399. PubMed ID: 34544179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.
    Araten DJ; Belmont HM; Schaefer-Cutillo J; Iyengar A; Mattoo A; Reddy R
    Am J Case Rep; 2020 Sep; 21():e927418. PubMed ID: 32917848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [With paroxysmal nocturnal haemoglobinuria and treatment with eculizumab].
    Algado JT; Luque R; Nuñez R; Sanchez B
    Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):109-10. PubMed ID: 22197277
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
    Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
    Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
    Guasch A
    Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585
    [No Abstract]   [Full Text] [Related]  

  • 10. Terminal complement inhibition dampens the inflammation during COVID-19.
    Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
    Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Waheed A; Kuter DJ
    Am J Hematol; 2021 Jul; 96(7):E235-E237. PubMed ID: 33844861
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey.
    Barcellini W; Fattizzo B; Giannotta JA; Quattrocchi L; Aydin S; Barone F; Carbone C; Pomponi F; Metafuni E; Beggiato E; Sica S; Di Bona E; Lanza F; Notaro R; Iori AP
    Br J Haematol; 2021 Sep; 194(5):854-856. PubMed ID: 34036575
    [No Abstract]   [Full Text] [Related]  

  • 14. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
    McQuillen DP; Ram S
    Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.
    Gerber GF; Yuan X; Yu J; Cher BAY; Braunstein EM; Chaturvedi S; Brodsky RA
    Blood; 2021 Jul; 137(26):3670-3673. PubMed ID: 33945618
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
    Röth A; He G; Tong H; Lin Z; Wang X; Chai-Adisaksopha C; Lee JH; Brodsky A; Hantaweepant C; Dumagay TE; Demichelis-Gómez R; Rojnuckarin P; Sun J; Höglund M; Jang JH; Gaya A; Silva F; Obara N; Kelly RJ; Beveridge L; Buatois S; Chebon S; Gentile B; Lundberg P; Sreckovic S; Nishimura JI; Risitano A; Han B
    Am J Hematol; 2024 Sep; 99(9):1768-1777. PubMed ID: 38884175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective eculizumab therapy followed by BMT in a boy with paroxysmal nocturnal hemoglobinuria.
    Oshiro H; Goi K; Akahane K; Inukai T; Sugita K
    Pediatr Int; 2015 Apr; 57(2):e27-9. PubMed ID: 25868955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unusual presentation of paroxysmal nocturnal haemoglobinuria.
    Sanchez-Petitto G; Drachenberg CB; Mannuel HD; Law JY; Zimrin AB; Baer MR
    Br J Haematol; 2020 Feb; 188(3):347. PubMed ID: 31750542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.